$P100 Efficacy of anifrolumab in multi-refractory skin manifestations of systemic lupus erythematosus: case series$

P100 Efficacy of anifrolumab in multi-refractory skin manifestations of systemic lupus erythematosus: case series

Bibliographic Details
Main Authors:	George Bertsias, Sofia Flouda, Dimitrios Boumpas, Anastasios Karamanakos, Antonios Fanouriakis, Evgenia Emmanouilidou
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Lupus Science and Medicine

Similar Items

Anifrolumab for the treatment of refractory chilblain lupus erythematosus
by: Michael J. Woodbury, BS, et al.
Published: (2024-06-01)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
by: Michelle Petri, et al.
Published: (2023-01-01)

Management of Refractory Lupus Nephritis
by: Antonis Fanouriakis, et al.
Published: (2015-07-01)

Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs
by: Panagiotis Garantziotis, et al.
Published: (2022-05-01)

Changing paradigms in the treatment of systemic lupus erythematosus
by: Antonis Fanouriakis, et al.
Published: (2019-12-01)

607 Impact of anifrolumab on neuropsychiatric manifestations of depression and suicidality in patients with systemic lupus erythematosus
by: Raj Tummala, et al.
Published: (2022-12-01)

Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE
by: Jun Kang, et al.
Published: (2023-11-01)

P88 Baseline factors associated with subsequent development of incident nephritis in patients with systemic lupus erythematosus: a retrospective cohort study
by: Dimitrios T Boumpas, et al.
Published: (2024-03-01)

Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus
by: Antonis Fanouriakis, et al.
Published: (2019-03-01)

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
by: Myrto Nikoloudaki, et al.
Published: (2023-01-01)

Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus
by: Bishoy Abdelmalik, BS, et al.
Published: (2025-01-01)

425 Anifrolumab for the treatment of refractory cutaneous lupus erythematosus in patients: interim analysis of real-world outcomes
by: Oluwadamilola Oke, et al.
Published: (2024-04-01)

Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease
by: Dimitrios T Boumpas, et al.
Published: (2020-11-01)

Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)
by: E. Parriel, et al.
Published: (2025-03-01)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
by: Kyriakos A. Kirou, et al.
Published: (2022-08-01)

Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the “Attikon” Lupus Cohort
by: Dionysis Nikolopoulos, et al.
Published: (2022-05-01)

Refractory dermatomyositis responsive to anifrolumab
by: Phillip S. Ang, BA, et al.
Published: (2024-01-01)

Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy
by: Dimitrios Nikolakis, et al.
Published: (2023-04-01)

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
by: Alessia Alunno, et al.
Published: (2019-08-01)

Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab
by: Rebecca G. Gaffney, MD, et al.
Published: (2024-02-01)

Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: Systematic Review with Network Meta-analysis
by: Rawish Fatima, et al.
Published: (2023-05-01)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
by: Zhihui Liu, et al.
Published: (2022-09-01)

Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
Published: (2023-08-01)

LBP5 Real-life data of anifrolumab as a treatment for systemic lupus erythematosus (SLE)
by: Roxana González Mazarío, et al.
Published: (2024-03-01)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
by: Felten R, et al.
Published: (2019-05-01)

Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
Published: (2024-05-01)

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
by: Giovanni Paolino, et al.
Published: (2023-10-01)

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
by: Ian N Bruce, et al.
Published: (2022-12-01)

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
by: Nick Ballew, et al.
Published: (2022-12-01)

The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus
by: Aggelos Banos, et al.
Published: (2023-03-01)

28 JAK-STAT inhibitors in systemic lupus erythematosus
by: Antonis Fanouriakis
Published: (2023-09-01)

Alopecia secondary to severe discoid lupus responding to anifrolumab
by: Shannon Han, BS, et al.
Published: (2023-10-01)

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
by: Dimitrios T Boumpas, et al.
Published: (2020-09-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01)

Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study
by: Alessandra Bortoluzzi, et al.
Published: (2025-01-01)

LBP6 Early access program experience of anifrolumab in systemic lupus erythematosus patients in a Portuguese single center cohort
by: Mariana Brandão, et al.
Published: (2024-03-01)

O13 Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study
by: Dimitrios T Boumpas, et al.
Published: (2024-03-01)

P75 Molecular exploration of systemic lupus erythematosus (SLE) sexual dimorphism uncovers a crucial role of SMC1A in transcriptional regulation of inflammation
by: Prodromos Sidiropoulos, et al.
Published: (2024-03-01)

Anifrolumab Study for Treatment Effectiveness in the Real World (ASTER) among patients with systemic lupus erythematosus: protocol for an international observational effectiveness study
by: Marta Mosca, et al.
Published: (2024-11-01)